Catalent, Somerset
Catalent to sell New Jersey facility
Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday. Catalent provides contract manufacturing services and performs fill-finish work,
Catalent to sell Somerset oral solids facility
Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to contract manufacturer Ardena. Financial details of the agreement, which is expected to close in early 2025,
Catalent to sell Somerset HQ
The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, which is in talks with Novo Holdings for a $16.5 billion acquisition.
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset,
Catalent to Sell Somerset Oral Solids Facility to Ardena
Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset to Ardena
Catalent To Sell Oral Solids Development Facility In Somerset, NJ To Ardena
Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer
BioSpace5h
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...
FiercePharma2d
Catalent offloads New Jersey manufacturing plant, HQ to Belgian CDMO Ardena
Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...
Catalent, Inc. (NYSE:CTLT) Receives $59.83 Average Target Price from Analysts
Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have received an average recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight ...
BioSpace5d
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent
Somerset facility State-of-the art facility for clinical and commercial manufacturing of oral dosage forms. Ghent, Belgium, ...
bovnews1d
Stock Shock: The Unpredictable Rise and Fall of CTLT—What’s Driving the Drama?
On Monday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.65 which represents a slight increase of $0.20 or 0.33% from the prior close of $60.45. The stock opened at $60.5 and ...
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...
STAT5d
A setback for the Denali-Sanofi partnership
Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...